Filter Results
:
(264)
Show Results For
-
All HBS Web
(264)
- News (105)
- Research (112)
- Events (1)
- Multimedia (3)
- Faculty Publications (36)
Show Results For
-
All HBS Web
(264)
- News (105)
- Research (112)
- Events (1)
- Multimedia (3)
- Faculty Publications (36)
- 20 Sep 2011
- First Look
First Look: September 20
on Cancer: Integrative Research Centers at the Dana Farber Cancer Institute Heidi K. Gardner, Edo Bedzra, and Shereef M. ElnahalHarvard Business School Case 412-029 Dr. Barrett Rollins, chief scientific...
View Details
Keywords:
Sean Silverthorne
- 30 Aug 2016
- First Look
August 30, 2016
forthcoming Journal of Marketing Research Incentives versus Reciprocity: Insights from a Field Experiment By: Chung, Doug J., and Das Narayandas Abstract—We conduct a field experiment in which we vary the sales force compensation scheme...
View Details
Keywords:
Carmen Nobel
- 07 Jun 2016
- First Look
June 7, 2016
strategic, financial, and operational objectives. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=51110 May 2016 Oncology How the Affordable Care Act Has Affected Cancer Care in the United States: Has Value for View Details
Keywords:
Sean Silverthorne
- September 2020
- Case
Minerva 2010: Turbulent Times
By: John R. Wells and Benjamin Weinstock
In 2010, amid a flurry of new discoveries, Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), raised $6.6 million to test her new cancer drugs in mice. It had been more than 6 years since she had announced that she and her small team at...
View Details
Wells, John R., and Benjamin Weinstock. "Minerva 2010: Turbulent Times." Harvard Business School Case 721-390, September 2020.
- 15 Apr 2014
- First Look
First Look: April 15
Purchase this case: http://hbr.org/product/pepsico-profits-and-food-the-belt-tightens/an/314055-PDF-ENG Harvard Business School Case 313-012 Cancer Treatment Centers of America® (A) Cancer Treatment Centers...
View Details
Keywords:
Sean Silverthorne
- 28 Feb 2019
- Cold Call Podcast
Pursuing Precision Medicine at Intermountain Healthcare
- May 2021
- Article
Value-Based Healthcare in Urology: A Collaborative Review
By: Chanan Reitblat, Paul A. Bain, Michael E. Porter, David N. Bernstein, Thomas W. Feeley, Markus Graefen, Santosh Iyer, Matthew J. Resnick, C.J. Stimson, Quoc-Dien Trinh and Boris Gershman
Context:
In response to growing concerns over rising costs and major variation in quality, improving value for patients has been proposed as a fundamentally new strategy for how healthcare should be delivered, measured, and... View Details
In response to growing concerns over rising costs and major variation in quality, improving value for patients has been proposed as a fundamentally new strategy for how healthcare should be delivered, measured, and... View Details
Keywords:
Value-based Healthcare;
Integrated Practice Units;
Outcome Measurement;
Time-Driven Activity-Based Costing;
Health Care and Treatment;
Value;
Cost Management;
Strategy;
Outcome or Result;
Measurement and Metrics
Reitblat, Chanan, Paul A. Bain, Michael E. Porter, David N. Bernstein, Thomas W. Feeley, Markus Graefen, Santosh Iyer, Matthew J. Resnick, C.J. Stimson, Quoc-Dien Trinh, and Boris Gershman. "Value-Based Healthcare in Urology: A Collaborative Review." European Urology 79, no. 5 (May 2021): 571–585.
- 06 Sep 2006
- Lessons from the Classroom
Mixing Students and Scientists in the Classroom
niche." His on-going research at HBS synthesizes elements of history, sociology, business, and statistics. In the classroom, Fleming has carved out a place for himself helping students from diverse disciplines learn to work together...
View Details
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (A)
By: Sandra J. Sucher and Stacy McManus
Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the...
View Details
Keywords:
Decision Making;
Health Testing and Trials;
Innovation and Invention;
Markets;
Distribution;
Product Development;
Production;
Problems and Challenges;
Research;
Research and Development;
Complexity;
Biotechnology Industry;
Pharmaceutical Industry
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (A)." Harvard Business School Case 603-043, April 2003. (Revised October 2004.)
- Person Page
Comments on my health
February 22, 2010
The doctors have been pleasantly surprised that I have responded to therapy better than they would have imagined. I have been greatly blessed through the miracle of medical science. I also attribute doing better to the faith and prayers... View Details
- May 2023 (Revised June 2023)
- Case
Novartis (A): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,...
View Details
Keywords:
Health Care and Treatment;
Business Model;
Leadership;
Pharmaceutical Industry;
Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (A): Reimagining Medicine." Harvard Business School Case 723-443, May 2023. (Revised June 2023.)
- May 2023 (Revised June 2023)
- Supplement
Novartis (C): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,...
View Details
Keywords:
Health Testing and Trials;
Health Care and Treatment;
Business Model;
Problems and Challenges;
Pharmaceutical Industry;
Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (C): Reimagining Medicine." Harvard Business School Supplement 723-445, May 2023. (Revised June 2023.)
- May 2023 (Revised June 2023)
- Supplement
Novartis (B): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,...
View Details
Keywords:
Health Care and Treatment;
Business Model;
Production;
Business Strategy;
Pharmaceutical Industry
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (B): Reimagining Medicine." Harvard Business School Supplement 723-444, May 2023. (Revised June 2023.)
- December 2019
- Technical Note
Technical Note on Bayesian Statistics and Frequentist Power Calculations
By: Amitabh Chandra and Ariel Dora Stern
This Technical Note provides an introduction to Bayes’ Rule and the statistical intuition that stems from it. In this note, we review the concepts that underlie Bayesian statistics, and we offer several simple mathematical examples to illustrate applications of Bayes’...
View Details
Chandra, Amitabh, and Ariel Dora Stern. "Technical Note on Bayesian Statistics and Frequentist Power Calculations." Harvard Business School Technical Note 620-032, December 2019.
- August 2023
- Case
Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company
By: Satish Tadikonda and Brad Prosek
Constellation Pharmaceuticals was a company focused on epigenetic therapies for cancer patients. Despite a promising start and an early deal with a leading biopharma company, the company weathered twin setbacks in the end of a major research collaboration and the...
View Details
Keywords:
Mergers and Acquisitions;
Health Care and Treatment;
Organizational Change and Adaptation;
Research and Development;
Business Strategy;
Pharmaceutical Industry;
United States
Tadikonda, Satish, and Brad Prosek. "Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company." Harvard Business School Case 824-032, August 2023.
- 22 Mar 2021
- Research & Ideas
How to Learn from the Big Mistake You Almost Make
Steinberg, and Ann Raldow, and medical physicist Nzhde Agazaryan. A spectrum of close calls The research team wanted to understand the role of psychological safety—defined as “the shared belief that interpersonal risk-taking is safe”—in...
View Details
- 22 Feb 2022
- Research & Ideas
Lack of Female Scientists Means Fewer Medical Treatments for Women
Women are more likely to invent medical treatments for endometriosis, cervical cancer, and other female conditions, but the dearth of women scientists limits the potential for such life-saving innovations. Female research teams are 35...
View Details
Keywords:
by Kristen Senz
Malcolm S. Salter
Malcolm Salter has been a member of the Harvard Business School faculty since 1967. His teaching and research focus on issues of corporate strategy, organization, and governance.
In addition to teaching at HBS, he has held faculty positions at the Harvard... View Details
- March 2021 (Revised January 2023)
- Case
The Trouble with TCE
By: Vincent Pons, Rafael Di Tella and Galit Goldstein
Trichloroethylene, or TCE, was a chemical used by tens of thousands of businesses in the United States. It was an affordable tool for many. Yet, TCE had been associated with important health risks, including cancer and autoimmune disease. TCE potentially posed other...
View Details
Keywords:
Trichloroethylene;
Toxicity;
Lobbying;
Chemicals;
Health Disorders;
Governing Rules, Regulations, and Reforms;
Policy;
Ethics;
Business and Government Relations;
Chemical Industry;
United States
Pons, Vincent, Rafael Di Tella, and Galit Goldstein. "The Trouble with TCE." Harvard Business School Case 721-031, March 2021. (Revised January 2023.)